

GOVERNMENT OF THE DISTRICT OF COLUMBIA MURIEL BOWSER, MAYOR

Government of the District of Columbia Department of Health

Prescription Drug Monitoring Program Advisory Committee Meeting

899 NORTH CAPITOL ST. NE – 2ND FLR. WASHINGTON, DC 20002 WebEx VIRTUAL MEETING

August 17, 2021 10AM – 11:30AM

AGENDA

899 North Capitol Street NE | 2nd Fl, Washington, DC 20002 | E doh.pdmp@dc.gov | https://dchealth.dc.gov/pdmp

CALL TO ORDER:

PRESIDING:

COMMITTEE MEMBERSHIP/ATTENDANCE:

ADVISORY		
COMMITTEE		
MEMBERS:		
	Jacqueline Watson, DO, MBA, DC Health Chief of Staff	
	Aisha Nixon, MPT, CPM, Board of Medicine Executive Director	
	Shauna White, PharmD, RPh, MS, Board Of Pharmacy Executive Director	
	Natalie Kirilichin, MD, MPH, Emergency Medicine Physician	
	Sheri Doyle, MPH, Consumer Member	
	Commander Ramey Kyle, Metropolitan Police Department	
	Lakisha Stiles, CPhT, Pharmacy Technician	
PDMP STAFF:	Justin Ortique, PharmD, RPh, Supervisory Pharmacist	
	Brittany Allen, MPH, Program Specialist	
	Erica Loadman, PharmD, RPh, Pharmacist	
LEGAL STAFF:	Carla Williams, Esq, Senior Assistant General Counsel, PDMP	
LEGAL STAFF.	Attorney Advisor	
VISITORS:		

899 North Capitol Street NE | 2nd Fl, Washington, DC 20002 | E <u>doh.pdmp@dc.gov</u> | <u>https://dchealth.dc.gov/pdmp</u>

Open Session Agenda Qurom:

)817-O-01	Welcome & Introductions
	Chair Report
	Charge of the Committee
	The Committee shall convene at least two (2) times per year to advise the Director:
	(a) On the implementation and evaluation of the Program;
	(b) On the establishment of criteria for indicators of possible misuse or abuse of covered substances;
	(c) On standardization of the methodology that should be used for analysis and interpretation of prescription monitoring data;
	 (d) In determining the most efficient and effective manner in which to disclose the findings to proactively inform prescribers regarding the indications of possible abuse or misuse of covered substances;
	(e) On identifying drugs of concern that demonstrate a potential for abuse and that should be monitored; and
	(f) Regarding the design and implementation of educational courses for:
	 (1) Persons who are authorized to access the prescription monitoring information;
	(2) Persons who are authorized to access the prescription monitoring information, but who have violated the laws or breached professional standards involving the prescribing, dispensing, or use of any controlled substances or drugs monitored by the Program;
	(3) Prescribers on prescribing practices, pharmacology, and identifying, treating, and referring patients addicted to or abusing controlled substances or drugs monitored by the Program; and
	(4) The public about the use, diversion and abuse of, addiction to, and treatment for the addiction to controlled substances or drugs monitored by the Program.
0817-O-02	Approval of April 2021 PDMP Advisory Committee Meeting Minutes (a) Minutes from April 2021 Meeting

899 North Capitol Street NE | 2nd Fl, Washington, DC 20002 | E doh.pdmp@dc.gov | https://dchealth.dc.gov/pdmp

0817-O-03	Report from Attorney Advisor						
	(a) PDMP Legislative Update						
		P is proposing language for the Prese	cription Drug Monitoring				
		Amendment Act of 2021. This legislat					
	Prescription Drug Monitoring Program Act of 2013 to expand the						
	Director's discretionary disclosures to include disclosing aggregate and						
	summary data that has been processed to remove personal identifiers						
	to public or private entities for statistical, research, educational, or grant						
	applications purposes; and enable the Director to charge a fee to offset						
	the opera	tional costs to disclose information.					
		ndment will bring the District's Prescri					
		more in line with other states and allo					
		disclose redacted, aggregate and sum	nmary data to serve the				
	public interest.						
0047 0 04	Dreament lindete	-					
0817-O-04	Program Updates (a) PDMP Registration Statistics and Compliance						
	(h) Outropole	A ativitia a					
	(b) Outreach	Activities					
	Past	udience	Derticipent Count				
		C Hospital Association Joint Committee	Participant Count 41 participants				
		eeting					
		C Hospital Association newsletter ad	Disseminated to				
			members via email				
	April 21 M	edical Society of DC	8 participants + video				
	April 23 M	andatory Query Lunch and Learn	posted to website 104 participants				
		arxCare webinar	54 participants				
		andatory Query Lunch and Learn	55 participants				
		arxCare webinar	29 participants				
		HR/Gateway Integration webinar	11 participants				
	June 29 El	HR/Gateway Integration webinar	28 participants				
	Future						
	Date	Торіс					
	September TBD	EHR/Gateway Integration overview					
	November TBD	EHR/Gateway Integration overview					
	(c) Appual P	eport					
	(c) Annual Report Under DC Health leadership review						
	onder BV						
	(d) Pharmac	y Submission Practices Audit					
		·					
0817-O-05	Presentation and						
	Indicators of Misuse and Abuse						
	Erica Loadman, PharmD, RPh, Pharmacist						
	The Indicators of Misuse and Abuse presentation describes the PDMP data						

899 North Capitol Street NE | 2nd Fl, Washington, DC 20002 | E doh.pdmp@dc.gov | https://dchealth.dc.gov/pdmp

	indicators of prescription drug abuse and misuse currently available to practitioners via the PMP Aware platform. The presentation also includes some additional indicators found in literature which may be potentially useful to PDMP users.
0817-O-06	 Grant Updates (a) Districtwide Gateway Integration DC PDMP outreach has included two integration webinars and there are two additional webinars scheduled in 2021. Combined, these webinars reached nearly 40 participants. As a result, 13 health entities have connected to the DC PDMP through Gateway Integration since the April 2021 meeting. A total of 44 entities have connected to the DC PDMP through Gateway Integration. (b) District Addiction Consultation Services Launched July 1, 2021 districtacs.org
	 (c) Opioid Communications Campaign My Recovery DC Engage Strategies LLC Ads began running in July 2021 <u>myrecoverydc.org/</u>
0817-O-07	 PDMP Best Practice Checklist Updates and Discussion Disseminate prescriber report cards quarterly
0817-O-08	 PDMP Related Articles for Discussion Pepin, D., Hulkower, R., & McCord, R. F. (2020). How Are Telehealth Laws Intersecting With Laws Addressing the Opioid Overdose Epidemic?. <i>Journal of public health management and practice : JPHMP</i>, <i>26</i>(3), 227–231. Ball, S. J., Simpson, K., Zhang, J., Marsden, J., Heidari, K., Moran, W. P., Mauldin, P. D., & McCauley, J. L. (2021). High-Risk Opioid Prescribing Trends: Prescription Drug Monitoring Program Data From 2010 to 2018. <i>Journal of public health management and practice : JPHMP</i>, <i>27</i>(4), 379–384.
	 Shreffler, J., Shaw, I., Berrones, A., & Huecker, M. (2021). Prescription History Before Opioid Overdose Death: PDMP Data and Responsible Prescribing. <i>Journal of public health management and practice :</i>

899 North Capitol Street NE | 2nd Fl, Washington, DC 20002 | E <u>doh.pdmp@dc.gov</u> | <u>https://dchealth.dc.gov/pdmp</u>

	<i>JPHMP, 27</i> (4), 385–392.				
0817-O-09	District of Columbia Department of Health COVID-19 Health and Healthcare Recovery Report				
0817-O-10	Committee Member Updates				
0817-O-11 Matters for Consideration	Future Meeting Dates • December 21, 2021 • April 19, 2022 • August 16, 2022				
Comments from the Public					
Motion to Adjourn the Open Session	Madam Chair, I move that the Committee close the meeting. (Roll Call Vote)				

This concludes the meeting.

Meeting Adjourned at____: